专题:Animal testing and alternatives

This cluster of papers focuses on improving the reporting and conduct of animal research studies, with an emphasis on the use of ARRIVE guidelines, cytotoxicity assays, ethical considerations, systematic reviews, in vitro testing methods, and addressing publication bias. It also discusses the challenges in translating findings from animal studies to human applications and the determination of sample sizes for preclinical studies.
最新文献
Drug Development Failure from Preclinical, Clinical, and Industrial Perspectives

article Full Text OpenAlex

Revisiting ISO 10993‐5 In Vitro Cytotoxicity Standard Tests for Evaluation of Extracellular Matrix‐Based Biomaterials

article Full Text OpenAlex

Reimagining human-centric drug development with new approach methodologies

article Full Text OpenAlex

New approach methodologies for drug discovery

article Full Text OpenAlex

Never-ending Acronym Madness: Proposing a harmonized definition for NAMs

article Full Text OpenAlex

The age of animal experiments is waning. Where will science go next?

article Full Text OpenAlex

Foreign body reaction: towards a macrophage-centered adverse outcome pathway for fibrotic encapsulation

article Full Text OpenAlex

Innovations in skin microphysiological systems for nonclinical testing and FDA modernization

article Full Text OpenAlex

Organoids in drug development: from predictive models to regulatory integration

article Full Text OpenAlex

The FDA’s plan to phase out animal testing

article Full Text OpenAlex

近5年高被引文献
Why 90% of clinical drug development fails and how to improve it?

article Full Text OpenAlex 1750 FWCI162.332

ProTox 3.0: a webserver for the prediction of toxicity of chemicals

article Full Text OpenAlex 1650 FWCI317.736

Planning experiments: Updated guidance on experimental design and analysis and their reporting III

editorial Full Text OpenAlex 520 FWCI0

Role of animal models in biomedical research: a review

article Full Text OpenAlex 510 FWCI88.4269

Optimization of the Hemolysis Assay for the Assessment of Cytotoxicity

article Full Text OpenAlex 469 FWCI124.2709

New approach methodologies in human regulatory toxicology – Not if, but how and when!

article Full Text OpenAlex 390 FWCI103.3383

FDA Modernization Act 2.0 allows for alternatives to animal testing

article Full Text OpenAlex 379 FWCI100.4847

FDA no longer has to require animal testing for new drugs

article Full Text OpenAlex 367 FWCI98.3829

Phenotypic drug discovery: recent successes, lessons learned and new directions

review Full Text OpenAlex 353 FWCI8.4431

FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches

article Full Text OpenAlex 346 FWCI91.4146